Find Academic Supervisors

Erin PrestwichView profile

Assistant Professor

• Nucleic Acid Modifications
• Epigenetics
• Epitranscriptomics
• +12 more

Erin Prestwich is an Assistant Professor in the Department of Medicinal and Biological Chemistry at the University of Toledo within the College of Pharmacy and Pharmaceutical Sciences. Her research focuses on leveraging analytical chemistry, mass spectrometry, and chemical biology to explore nucleic acid modifications in disease pathophysiology, particularly in bacterial biofilms and inflammatory conditions. Ph.D. in Chemistry, Boston College (2006) B.A. in Chemistry, Wellesley College (1999) Her laboratory investigates how epigenetic and epitranscriptomic changes influence biofilm behavior, antibiotic resistance, and pathologies like diabetes and inflammatory bowel disease. This involves developing robust methods for RNA and DNA modification quantification, MALDI-based imaging techniques, and studying oxidative stress responses in microbial and mammalian systems. Recent publications highlight trends in RNA and DNA damage analysis, biofilm subpopulation characterization, and pharmaceutical development. These span fields such as mass spectrometry, microbiology, immunology, and disease biomarker discovery. Contact: erin.prestwich@utoledo.edu

• Synthetic Biology
• Genetic Engineering
• RNA-based Biotechnology
• +8 more

Prof. Dr. Daniel Schindler is a Visiting Scientist at the Max Planck Institute for Terrestrial Microbiology in Marburg, Germany, affiliated with the DNA Service Unit . His work focuses on synthetic biology, genetic engineering, and RNA-based technologies. Research Interests : Daniel Schindler's research spans synthetic biology and microbial genomics, with emphasis on RNA engineering, DNA assembly techniques, and metabolic pathway optimization. He explores the application of Golden Gate cloning, synthetic secondary chromosomes, and CRISPR tools for precise genetic manipulation. Recent Publications : His work highlights advancements in synthetic small RNA design, high-throughput DNA assembly, and phage engineering. Themes include microbial systems biology, enzyme evolution, and scalable genome modification. Contact : Email: daniel.schindler@mpi-marburg.mpg.de Phone: +49 6421 178 530 Address: Karl-von-Frisch-Strasse 10, 35043 Marburg, Germany

Mohamed BenderdourView profile

Professor

• Biochemistry of lipid peroxidation aldehydes
• Joint diseases
• Cellular metabolism alteration
• +7 more

Mohamed Benderdour is a Full Professor in the Department of Surgery at the University of Montreal and a Regular researcher at the Research Center of the Sacré-Coeur Hospital of Montreal, where he contributes to the Trauma – acute care research axis. His academic career spans over two decades with significant contributions to biochemical research related to joint diseases. Dr. Benderdour's research primarily focuses on the biochemistry of lipid peroxidation aldehydes and their implications in joint diseases, particularly osteoarthritis. His work investigates how aldehydes alter cellular metabolism and cause post-translational modifications of proteins, with specific attention to cell signaling mechanisms involving protein kinases and transcription factors. He has extensively studied 4-hydroxynonenal and its role in osteoarthritis pathogenesis, exploring mechanisms of gene regulation and promoter analysis in joint tissue pathology. Analysis of Dr. Benderdour's publication history reveals an evolution from fundamental biochemical mechanisms to increasingly translational research. His recent work shows strong emphasis on RNA modifications in osteoarthritis (epitranscriptomics), nanotechnology approaches for therapeutic delivery (particularly chitosan-based nanovectors for siRNA), and the pathophysiology of immunoporosis. His publications demonstrate a progression toward developing therapeutic applications from basic science discoveries. Dr. Benderdour maintains a productive research career with publications spanning molecular biology, biochemistry, rheumatology, and nanotechnology. His work bridges basic science with potential clinical applications in orthopedics and joint disease treatment, reflecting a commitment to advancing both scientific understanding and potential therapeutic interventions for osteoarthritis and related conditions.

Chengfeng YangView profile

Professor

• RNA dysfunction in carcinogenesis
• Cancer therapy resistance
• Non-coding RNAs
• +5 more

Dr. Chengfeng Yang is a Professor in the Department of Pathology at the Renaissance School of Medicine, Stony Brook University. His research program focuses on Oncogenic Drivers and Mechanisms of Carcinogenesis, with particular emphasis on RNA dysfunction in cancer development and resistance to therapies. Dr. Yang received his medical degree from Tongji Medical University, completed his PhD at National University of Singapore, and conducted postdoctoral training at New York University and University of Pennsylvania. This diverse educational background has equipped him with expertise spanning medicine, molecular biology, and toxicology. His laboratory investigates the role and mechanism of RNA abnormal expression and post-transcriptional modifications in cancer initiation (carcinogenesis), progression (metastasis), and therapeutic resistance. The research is grounded in the recognition that human genome is pervasively transcribed, with a large portion transcribed as non-coding RNAs, especially long non-coding RNAs (lncRNAs). His work demonstrates how environmental carcinogens, particularly metals like hexavalent chromium and arsenic, dysregulate RNA molecules leading to cancer stem cell-like properties and tumorigenesis. Analysis of Dr. Yang's recent publication record reveals consistent productivity with expanding interdisciplinary connections, particularly between RNA biology, environmental toxicology, and microbiome research. His work bridges molecular biology, toxicology, and oncology, with significant focus on identifying dysfunctional RNA molecules as potential diagnostic markers and therapeutic targets for cancer prevention and treatment. Dr. Yang actively mentors undergraduate and graduate students in his laboratory, providing research opportunities to study the mechanisms of carcinogenesis. His laboratory serves as a hub for interdisciplinary cancer research at Stony Brook University, collaborating with researchers across multiple departments and institutions.

• Chemical Biology
• Cancer Metabolism
• Epigenetics
• +7 more

Jordan L. Meier, Ph.D. is a Senior Investigator and Head of the Epigenetics and Metabolism Section at the Chemical Biology Laboratory within the Center for Cancer Research at the National Cancer Institute, National Institutes of Health. His research bridges chemical biology, cancer metabolism, and epigenetic regulation, focusing on how metabolic states influence genomic signaling through chromatin modifying enzymes. Dr. Meier's educational background includes: Bachelor's degree in Chemistry from Creighton University (2004) Ph.D. in Chemistry from University of California-San Diego (2009), working under Professor Michael D. Burkart Postdoctoral training as an American Cancer Society fellow at California Institute of Technology with Professor Peter B. Dervan His research interests center on the intersection of metabolism and epigenetics, particularly how metabolic perturbations influence epigenetic signaling. Dr. Meier's laboratory develops chemical approaches to investigate metabolic and epigenetic signaling pathways in cancer, with special focus on acetyl-CoA mediated acetylation mechanisms and oncometabolite-driven cancers. His work aims to discover biological mechanisms underlying oncometabolite-driven cancers, develop new cancer diagnostics, and identify small molecules that inhibit epigenetic modifications through metabolic disruption. Analysis of Dr. Meier's publications reveals a consistent research trajectory exploring the chemical biology of metabolic-epigenetic crosstalk. His work spans from fundamental chemical probe development to cancer-relevant biological applications, with particular emphasis on acetylation-based signaling mechanisms, oncometabolite detection, and chemoproteomic mapping of metabolic enzyme targets. His research has significantly advanced understanding of how metabolites like fumarate and acyl-CoA derivatives regulate epigenetic processes in cancer. Notable recognition includes: American Cancer Society postdoctoral fellowship Dr. Meier actively mentors a diverse research team including postdoctoral fellows and postbaccalaureate researchers. His laboratory has developed innovative chemical tools and approaches that have enabled new avenues for understanding metabolic regulation of epigenetic processes. Current research includes development of the Fumarate Chemoproteomic Reactivity Database to enable community efforts in studying FH-regulated cysteines. The Chemical Biology Laboratory fosters a collaborative environment with active participation in symposia and scientific meetings. Dr. Meier's team engages in both fundamental chemical biology research and translational applications, with a particular focus on developing new approaches for cancer therapy, diagnosis, and chemoprevention based on metabolic-epigenetic connections.

• RNA Biochemistry
• Protein Synthesis
• Translation Mechanisms
• +5 more

Jinfan Wang is an Assistant Professor and UT Southwestern Endowed Scholar in the Department of Biochemistry at University of Texas Southwestern Medical Center (UTSW). He obtained his B.S. in Biotechnology from the University of Science and Technology Beijing (2010) and a Ph.D. in Biochemistry from Uppsala University (2016), where he studied prokaryotic translation under Dr. Anthony Forster. Supported by the Knut and Alice Wallenberg Foundation, he conducted postdoctoral research at Stanford University (2016–2023) with Dr. Jody Puglisi, developing single-molecule methods to study eukaryotic translation. His lab at UTSW combines quantitative biochemistry, structural biology, and genetics to investigate cytosolic and mitochondrial translation mechanisms. Education B.S., Biotechnology – University of Science and Technology Beijing (2010) Ph.D., Biochemistry – Uppsala University (2016) His research focuses on the dynamic interplay between mRNA structure, ribosome function, and translation regulation in eukaryotes. Using single-molecule fluorescence microscopy, his team established frameworks for understanding start codon recognition, elongation fidelity, and drug-induced translation arrest. Recent work explores mitochondrial translation and its dysregulation in human diseases. Key publications reveal insights into: Eukaryotic translation initiation (Cell 2022, Nature 2019) Ribosome interactions with modified mRNA (Nat Struct Mol Biol 2018) Engineering of translation systems (Nucleic Acids Res 2017) Kinetic bottlenecks in unnatural amino acid incorporation (ACS Chem Biol 2015) Scientific Awards Knut and Alice Wallenberg Foundation Postdoctoral Fellowship UT Southwestern Endowed Scholar Dr. Wang’s lab seeks to bridge fundamental translation mechanisms with therapeutic applications, particularly in diseases linked to mitochondrial dysfunction. They actively recruit graduate students, technicians, and postdocs for interdisciplinary research.

• Immunology
• Molecular Biology
• RNA Biology
• +5 more

Ana Rebane is a Professor of Molecular Medicine at the University of Tartu's Faculty of Medicine, Institute of Biomedicine and Translational Medicine since October 2019. Previously, she served as a Senior Research Fellow in RNA Biology (2016-2019) and in the Department of General and Molecular Pathology. She has held various research positions at the University of Tartu since 2004, with a visiting scientist position at the Swiss Institute of Allergy and Asthma Research (2010-2013) and a postdoctoral associate at Yale University (2000-2003). Her educational background includes a Doctor's Degree from the University of Tartu (1999) with a thesis on "Mammalian ribosomal protein S3a genes and intron-encoded small nucleolar RNAs U73 ans U82" under Andres Metspalu. She completed her PhD studies from 1995-1998 and earned her degree in Bioorganic Chemistry from Tartu University (1984-1989). Ana Rebane's research focuses on immunology, molecular biology, and RNA biology, particularly in the context of allergy, asthma, and skin conditions. Her work extensively examines the role of microRNAs in immune responses, inflammasome activation, and skin barrier function. She investigates how RNA modifications, particularly in keratinocytes, influence inflammatory responses in conditions like atopic dermatitis and psoriasis. Her research bridges basic molecular mechanisms with clinical applications, exploring therapeutic delivery systems like cell-penetrating peptides for RNA-based treatments. Her publication record shows a strong focus on molecular mechanisms of skin and respiratory inflammation, with recent work emphasizing RNA modifications, inflammasome biology, and innovative delivery systems for nucleic acid therapeutics. Her research demonstrates consistent progression from basic molecular mechanisms to translational applications, particularly in dermatological and respiratory conditions. 2020 Estonian National Science Award (medical sciences) 2019 Academic Leader of Eastern Europe, European Society of Dermatological Research 2015 The Eastern European Dermatology Research Award 2014 Research Fellow from European Society of Dermatological Research 2010 SCIEX stipendium to work at Swiss Institute of Allergy and Asthma Research 2000 Fellowship from NATO-NSF 1997 Fellowship from Finnish Government 1996 Fellowship from Nordic Council of Ministers Ana Rebane serves in significant administrative roles including Member of the University of Tartu Senate (since 2023), President of the Estonian Society of Human Genetics (since 2022), and Board Member of the same society (since 2020). She is an Associated Editor for Frontiers in Allergy (since 2020) and serves on the Reviewer Board of the Journal of Allergy and Clinical Immunology (since 2017). She has been an active member of several professional societies including the European Society of Dermatological Research and the European Academy of Allergy and Clinical Immunology. Her research activities are centered around the Institute of Biomedicine and Translational Medicine at the University of Tartu, where her team investigates molecular mechanisms of immune responses, particularly focusing on RNA biology and its implications for inflammatory skin and respiratory diseases. Her laboratory develops and applies advanced techniques for studying gene regulation, epigenetic modifications, and innovative therapeutic delivery systems.

• Chronic Traumatic Encephalopathy
• Gliomas
• Epigenetics
• +5 more

Clinical Associate Professor Michael Buckland is affiliated with the University of Sydney and serves as the Head of the Department of Neuropathology at Royal Prince Alfred Hospital . He is the founder of the Australian Sports Brain Bank and co-director of the Multiple Sclerosis Australia Brain Bank , with leadership roles in the Brain & Mind Centre and Brainstorm initiatives. His research focuses on Chronic Traumatic Encephalopathy , Gliomas , Epigenetics , and Neuroinflammatory diseases , with a strong emphasis on Neurodegenerative diseases and Molecular neuropathology . He employs Genetics , Pathology , and Translational Research to bridge clinical and molecular insights. Recent publications highlight work on immune checkpoint therapies for glioblastoma, neurotoxic elements in multiple sclerosis, and epitranscriptomic biomarkers for brain tumors. His collaborative studies span neuro-oncology , traumatic brain injury , and AI-driven pathology innovations. No scientific awards or student advisement details were explicitly mentioned.

• Genomics
• Bioinformatics
• Haematopoiesis
• +5 more

Louie Van de Lagemaat is a bioinformatician at the University of Aberdeen's Centre for Genome-Enabled Biology and Medicine (School of Medicine, Medical Sciences and Nutrition), joining in October 2021. He holds a PhD in Genetics from the University of British Columbia (2006) and has extensive experience in genomic data analysis. Research Interests : Haematopoiesis, molecular neuroscience, and transcriptomics using high-throughput sequencing technologies. Expertise : ChIP-seq, RNA-seq, Ribo-seq, and meRIP-seq analysis, with a focus on HLA allele heterozygosity and epigenetic regulation. Collaborations : Active in interdisciplinary studies with researchers in stem cell biology, cancer genomics, and neurogenetics.

Mati KarelsonView profile

Professor

• Computational Chemistry
• QSAR Modeling
• Drug Design
• +5 more

Mati Karelson is a Full Professor at the University of Tartu's Institute of Chemistry in Estonia, where he has maintained a continuous academic appointment since September 1992. With an educational background in Chemistry from Tartu State University (1992-1995), he has established himself as a leading researcher in computational chemistry and drug design. Professor Karelson's research spans multiple disciplines with a strong focus on computational approaches to drug discovery . His work prominently features: Quantitative Structure-Activity Relationship (QSAR) modeling Molecular docking and virtual screening Epitranscriptomics, particularly RNA methylation (m6A) Neurodegenerative disease research, especially Parkinson's disease Antiviral drug development targeting HIV and flaviviruses His recent publications (2023-2025) demonstrate a strong emphasis on the intersection of computational chemistry and biological applications, particularly in developing small molecule modulators of RNA methylation pathways and their therapeutic potential for neurological disorders and viral infections. Professor Karelson has published 238 papers with over 44,875 reads and 13,947 citations, reflecting significant impact in his field. His research collaborations span multiple institutions internationally, working with experimental biologists to validate computational predictions. The interdisciplinary nature of his work bridges computational chemistry with neuroscience, virology, and molecular biology, creating a robust research program with translational potential.

Robert SchneiderView profile

Professor

• Epigenetics
• Chromatin Biology
• Metabolism-Epigenetics Crosstalk
• +4 more

Prof. Robert Schneider serves as Professor at Ludwig-Maximilians-Universität München's Faculty of Biology and Director of the Institute of Functional Epigenetics at Helmholtz Zentrum München. He leads Project A20 within the Collaborative Research Center 1064, investigating how metabolic enzymes and their products regulate chromatin dynamics and gene expression. His dual appointments position him at the nexus of academic research and translational biomedical science in Munich's vibrant research ecosystem. His academic journey began with Biology Diploma studies (1990-1996) and doctoral research (1996) at LMU Munich under Prof. Regine Kahmann. This was followed by an EMBO fellowship at Cambridge's Gurdon Institute (2000-2004), a Max Planck Research Group leadership in Freiburg (2005-2012), and Director de Recherche position at Strasbourg's IGBMC (2012-2016) before his current roles. Research focuses on metabolite-chromatin crosstalk, particularly how short-chain acyl-CoAs drive histone lysine acylations to reprogram gene expression. The lab employs innovative approaches including metabolic enzyme recruitment to specific genes, in vitro chromatin reconstitutions, and single-cell tracing of transcriptional memory. Current work emphasizes RNA modification enzymes (e.g., METTL5/6) in pluripotency and the role of sugar metabolism in epigenetic inheritance. This research provides fundamental insights into how nutrition and metabolism shape genomic regulation with implications for cancer and developmental disorders. Recent publications (2017-2020) reveal a strategic expansion from histone modifications into RNA epigenetics and single-cell dynamics of metabolic-epigenetic interactions. The work consistently bridges biochemical mechanism with functional outcomes in stem cells and disease models, demonstrating increasing technical sophistication through integrative genomics and live-cell imaging approaches. Major recognitions include: ERC Starting Grant (2008) HFSP Career Development Award (2006) Chaire Gutenberg, University of Strasbourg (2012) Multiple labellisation awards from French research foundations (2012-2014) Epigenome Network of Excellence membership Mentorship occurs through structured PhD programs including CRC 1064's graduate initiatives and Helmholtz's doctoral training. The lab maintains active grants from DFG (CRC 1064), ERC, and collaborative consortia, supporting interdisciplinary projects that attract international talent. Prof. Schneider serves on editorial boards (PLOS Genetics) and selection committees, fostering global scientific exchange while maintaining a highly collaborative lab environment focused on mechanistic epigenetics. The Institute of Functional Epigenetics operates as a dynamic hub within Helmholtz Zentrum München, combining biochemical expertise with genomic and computational approaches. The lab's integration into CRC 1064 enables synergistic collaborations across Munich's research institutions, particularly in developing novel methods to probe metabolism-chromatin interfaces in real time.

YU HAOView profile

Professor

• Functional Genomics
• RNA Modification
• Plant Reproductive Development
• +5 more

YU HAO serves as Provost’s Chair Professor and Head of the Department of Biological Sciences at the National University of Singapore (NUS), Faculty of Science. He concurrently holds a Board Director position at Temasek Life Sciences Laboratory (TLL), Singapore, following his tenure as Executive Director (2015-2017) and Vice Dean of the Faculty of Science (2014-2017). His research focuses on elucidating plant regulatory networks through: Molecular mechanisms of RNA modifications (particularly m6A) Phytohormone signaling and molecular trafficking Floral transition and reproductive development Molecular breeding for urban farming applications Plant-based biomanufacturing platforms Recent publications (2022-2025) demonstrate his leadership in RNA epitranscriptomics, revealing how m6A modifications govern flowering time, stress responses, and hormone signaling in Arabidopsis and rice. His work bridges fundamental molecular mechanisms with agricultural innovation, emphasizing crop resilience and sustainable food systems. His scientific impact is recognized through prestigious honors: Elected Fellow of the Singapore National Academy of Science (2020) Singapore President Science Award (2013) National Research Foundation Investigatorship (2016) Three-time Provost’s Chair Professorship recipient (2017, 2020, 2023) Professor Yu actively shapes global plant science through editorial leadership in top journals (eLife, PLoS Genetics, Annual Review of Cell and Developmental Biology) and international advisory roles at institutions including the Chinese Academy of Sciences and Japan's National Institute for Basic Biology. His research program integrates molecular genetics, genomics, and biotechnology to address food security challenges.

Kumari KanchanView profile

Research Fellow

• Epigenetics
• Stem Cell Research
• Cancer Biology
• +3 more

Kumari Kanchan is a Postdoctoral Fellow at the Department of Molecular Biology, Umeå University, Sweden, working in the research group of Francesca Aguilo. Her office is located at the Hospital area (6K and 6L), Umeå. Her research focuses on epigenetics, stem cell biology, and cancer mechanisms. Key areas include the role of LSD1 in DNA methylation and stem cell differentiation, RNA modifications in breast cancer, and the development of DNA nanostructures for targeted cancer therapy. She also investigates biophysical interactions of drugs like artemisinin and the interplay between thyroid disorders and infectious diseases. Analysis of her recent publications (2020-2024) reveals a strong emphasis on epigenetic regulation in stem cells and cancer. Her work on LSD1 and CHD7 has uncovered critical mechanisms in mouse embryonic stem cell differentiation and chromatin dynamics. Additionally, she has pioneered the use of DNA nanostructures for miRNA delivery in cancer models and explored RNA epitranscriptomics in breast cancer pathogenesis. Scientific Awards: No awards were mentioned in the provided information. Advising and Grants: No details on student advising or research grants were available in the source material. Laboratory and Team: Dr. Kumari is an active member of the Francesca Aguilo research group at Umeå University's Department of Molecular Biology, contributing to projects on epigenetics and stem cell biology within the hospital campus environment.

• Genomic Conflicts of Interest
• Mammalian Embryology
• Epigenetics
• +6 more

Mads Lerdrup is an Associate Professor at the Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, where he leads research in the Molecular Aging Program. His work focuses on understanding how mammalian organisms handle inbuilt genomic conflicts of interest, particularly during embryonic development. Education Ph.D., University of Copenhagen (2007) M.Sc., University of Copenhagen (2002) Dr. Lerdrup's research centers on the remarkable genomic environment during mammalian fertilization and early embryonic development. His laboratory investigates extensive genomic reprogramming, epigenetic mark rewriting, and retrotransposon activity during these critical stages. He has pioneered the development of single-cell and low-input genome-wide methods to study replication stress in early mammalian embryos and the factors that instruct changes in oocyte and embryo epigenomes. His work has resulted in a comprehensive software suite for genome-wide data analysis (easeq.net). His recent publications demonstrate significant contributions to understanding transcription-replication collisions, histone modifications, DNA replication in embryos, and mitochondrial dysfunction related to aging. His research spans multiple high-impact journals including Nature Communications, Nature Biotechnology, Science Advances, and Nature Genetics. Dr. Lerdrup maintains an active research network with collaborations across multiple countries and has developed a side business as founder and owner of the consulting firm genessence (2022-2025). Research Activities Establishment of new single-cell and low-input genome-wide methods Identification of causes for replication stress in the early mammalian embryo Identification of factors instructing changes in oocyte and embryo epigenomes

• Biophysics
• Nanotoxicology
• Molecular Genetics
• +5 more

Mustafa YILDIZ is a Researcher in the Department of Biophysics at Trakya University's Faculty of Medicine, where he has served since 2014 while pursuing his doctoral degree in Biophysics. His academic foundation includes a Bachelor's in Physics (Sakarya University, 2009) and Master's in Biophysics (Trakya University, 2016). His educational background includes: Bachelor of Science in Physics, Sakarya University (2009) Master of Science in Biophysics, Trakya University (2016) - Thesis: Biophysical Methods Investigation on Cytotoxicity of Nanomaterials Using Mitochondrial Apoptotic Pathways Doctoral Candidate in Biophysics, Trakya University (Ongoing) YILDIZ's research spans Biophysics, Nanotoxicology, and Molecular Genetics , with emphasis on selenium biochemistry in reproductive disorders, epigenetic mechanisms in cancer, and nanomaterial cytotoxicity. His work integrates in vitro models with genetic polymorphism analysis to investigate oxidative stress pathways in preeclampsia, gestational diabetes, and carcinogenesis. Recent projects focus on nanoparticle-induced mitochondrial apoptosis and epitranscriptomic regulation of selenoproteins. Analysis of his 15 most recent publications (2019-2024) reveals dominant trends in epigenetic biomarker discovery (35% of articles), genetic polymorphisms in vascular/reproductive diseases (40%), and nano-biointerface toxicity (25%). Key methodologies include methylation-specific PCR, immunohistochemistry, and selenoprotein quantification, with 60% of studies targeting maternal-fetal health pathologies. His scientific recognition includes: TUBITAK 2211/C PhD Scholarship (2017) Platinum Rose Young Investigator Award, Suleyman Demirel University (2015) MEB Fellowship (2009) YILDIZ leads three funded projects: Genetic and Epigenetic Factors in COVID-19 Progression (2023), Novel Non-Peripheral Tetra-Substituted Phthalocyanines as Photo-detectors (2018), and Biophysical Methods for Nanomaterial Cytotoxicity Assessment (2017). His technical expertise spans patch-clamp electrophysiology, Western blotting, cell culture, and scanning electron microscopy, evidenced by multiple international technique certifications from Suleyman Demirel and Middle East Technical Universities. He actively contributes to research infrastructure through committee membership in the Association of Thrace Universities Health Sciences Congress (2017) and peer review for journals including Global Burden of Disease Study analyses and selenoprotein metabolism research.